| Name | Title | Contact Details |
|---|
As part of the state`s premier academic medical center, University of Missouri Health Care offers a full spectrum of care, ranging from primary care to highly specialized, multidisciplinary treatment for patients with the most severe illnesses and injuries. Patients from each of Missouri`s 114 counties are served by approximately 6,000 physicians, nurses and health care professionals at MU Health Care. MU Health Care is a part of University of Missouri Health System, which also includes the MU School of Health Professions, the MU School of Medicine, the MU Sinclair School of Nursing and University Physicians practice plan. University Hospital includes: The Frank L. Mitchell Jr., MD Trauma Center. A nationally accredited Cycle II Chest Pain Center and a nationally accredited Primary Stroke Center, the George D. Peak Memorial Burn and Wound Center. University of Missouri Women`s and Children`s Hospital is Missouri`s only hospital dedicated to women and children. It is the largest pediatric health care facility in mid-Missouri. Ellis Fischel Cancer Center is Missouri`s only hospital dedicated solely to cancer care. Missouri Orthopaedic Institute is the newest and largest freestanding orthopaedic center in mid-Missouri. The Missouri Psychiatric Center offers short-term, intensive inpatient treatment services for adults, adolescents and children at our facility adjacent to University Hospital.
Front Range Cancer Specialists is a Fort Collins, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
e4e is an IT-enabled Services and Business Process Outsourcing company that has deep domain and contextual expertise in the US Healthcare Business Services ecosystem, with an enviable client list of reputed companies. e4e was founded in 2000 and has over 2,500 employees globally, with offices in the U.S., India, and the Philippines. With over 150 years of cumulative senior management experience, we have the capability of delivering compelling business value to our clients, right shoring between our geographical sites and our best practices.
Cannus Partners Inc. operates as a specialty pharmaceutical company. The Company cultivates, processes, and distributes cannabis. Cannus Partners serves customers in the United States and Canada.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.